Tevogen Bio posts 51% reduction in nine-month operating loss

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) filed its third-quarter 2025 Form 10-Q, reporting a 51% reduction in operating loss for the nine months ended September 30, 2025, according to the company's statement.

The biotechnology company reported an operating loss of $21.5 million for the nine-month period, compared to $44.2 million in the same period of 2024. For the three-month period ended September 30, 2025, the operating loss was $5.7 million, a 6% decrease from $6.1 million in the prior year quarter.

Total operating expenses for the nine months were $21.5 million, down from $44.2 million in 2024. Research and development expenses decreased to $9.0 million from $28.2 million, while general and administrative expenses declined to $12.5 million from $16.0 million.

On a non-GAAP basis, excluding stock-based compensation, Tevogen reported an adjusted operating loss of $7.8 million for the nine months ended September 30, 2025, representing a 25% reduction compared to the same period in 2024. The adjusted quarterly operating loss was $2.5 million, down 10% from the prior year.

The company's net loss for the nine-month period was $21.6 million, compared to a net loss of $4.3 million in 2024. The quarterly net loss was $5.7 million versus $5.9 million in the prior year period.

"In today's environment, and likely for years to come, we believe the traditional high-cost, high-price drug development model will give way to efficient development and patient affordability while still achieving profitability," said Ryan Saadi, Chief Executive Officer, Chairman, and Founder of Tevogen.

The information is based on Tevogen's quarterly report filing with securities regulators.

You May Also Be Interested In